# EDGAR Filing Document

**Accession Number:** 0001936258
**File Stem:** 0001193125-23-006539
**Filing Date:** 2023-1
**Character Count:** 2984
**Document Hash:** fb2b15f325f7d9ad1c42743d63da8abe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-006539.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001193125-23-006539

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230111

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewAmsterdam Pharma Co N.V.
- **CENTRAL INDEX KEY:** 0001936258
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41562
- **FILM NUMBER:** 23524145

**BUSINESS ADDRESS:**
- **STREET 1:** GOOIMEER 2-35
- **CITY:** NARRDEN
- **STATE:** P7
- **ZIP:** 1411 DC
- **BUSINESS PHONE:** 35 206 2971

**MAIL ADDRESS:**
- **STREET 1:** GOOIMEER 2-35
- **CITY:** NARRDEN
- **STATE:** P7
- **ZIP:** 1411 DC

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NewAmsterdam Pharma Co B.V.
- **DATE OF NAME CHANGE:** 20220701

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of January 2023** 

**Commission File Number: 001-41562**

------

## NewAmsterdam Pharma Company N.V.
**(Exact name of registrant as specified in its charter)** 

------

**Gooimeer 2-35**

**1411 DC Naarden** 

**The Netherlands** 

**(Address of principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

On January 10, 2023, NewAmsterdam Pharma Company N.V. (the "Company") received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC, notifying the Company that its application to upgrade the listing of its ordinary shares from The Nasdaq Capital Market to The Nasdaq Global Market (the "Global Market") has been approved. The Company's ordinary shares will begin trading, with the same trading symbol, on the Global Market effective with the open of business on January 12, 2023.

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NewAmsterdam Pharma Company N.V.** | **NewAmsterdam Pharma Company N.V.** |
| January 11, 2023 | By: | /s/ David Topper |
|  |  | Name: David Topper<br> Title: Chief Financial Officer |

---